ALNY
Alnylam Pharmaceuticals, Inc.
ALNY has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ALNY overall on the model score.
ALNY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ALNY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8x | $157 | — |
| Forward | 22x | $157 | — |
| Cheap | 41x | $800 | +411% |
| Fair | 76x | $1,489 | +851% |
| Expensive | 1,731x | $33,895 | +21538% |
Historical ranges are pointers, not guarantees.
ALNY has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ALNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ALNY, but weaker profitability. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ALNY on the outlook, with more favorable valuation and profitability expectations.
ALNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.04 | -64% |
| Q3 2026 | $19.58 | +8413% |
| Q2 2026 | $5.70 | +$8.18 |
| Q1 2026 | $3.98 | +$6.08 |
| Q4 2025 | $2.03 | +$4.21 |
| Q3 2025 | $0.23 | +$2.81 |
| Q2 2025 | -$2.48 | -$1.92 |
| Q1 2025 | -$2.10 | +$0.54 |
| Q4 2024 | -$2.18 | +$1.34 |
ALNY has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ALNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +17% |
| Q2 2026 | $1.3B | +67% |
| Q1 2026 | $1.2B | +96% |
| Q4 2025 | $1.1B | +85% |
| Q3 2025 | $1.2B | +149% |
| Q2 2025 | $773.7M | +17% |
| Q1 2025 | $594.2M | +20% |
| Q4 2024 | $593.2M | +35% |
ALNY has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.7 points |
| Q2 2026 | 18% | +20 points |
| Q1 2026 | 23% | +20 points |
| Q4 2025 | 12% | +30 points |
| Q3 2025 | 29% | +45 points |
| Q2 2025 | -2.1% | -9.5 points |
| Q1 2025 | 3% | +12 points |
| Q4 2024 | -18% | +8.7 points |
ALNY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ALNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $271.2M | -13% |
| Q2 2026 | $292M | +109% |
| Q1 2026 | $48.7M | +$176M |
| Q4 2025 | $140.3M | +$244M |
| Q3 2025 | $313M | +692% |
| Q2 2025 | $139.4M | +20% |
| Q1 2025 | -$127.3M | -$32.8M |
| Q4 2024 | -$103.8M | -$58.7M |
ALNY has burned cash in most quarters: $752M over the past year, about three times what it generated the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ALNY on cash flow, with more consistent year-over-year improvement.
ALNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -241K shares |
| 1 year | +0.5% | +692K shares |
| 3 years | +5.1% | +6.7M shares |
| 5 years | +16% | +18.9M shares |
| Available history | +24% | +26.3M shares |
ALNY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ALNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -4.6x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
ALNY has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ALNY on leverage, with a lower net debt burden relative to earnings.
ALNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.6 | Oversold |
| Stochastic | 2.9 | Oversold |
ALNY's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ALNY PE vs Healthcare Sector
| Metric | ALNY | Sector median | Relative |
|---|---|---|---|
| PE | 8x | 26x | 69% below |
| PE % | 2 | 29 | 27 pts below |
ALNY has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ALNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $205.2 | 24% below |
| 20 week MA | $233.7 | 33% below |
| 50 week MA | $293.0 | 47% below |
| 100 week MA | $314.6 | 50% below |
| 200 week MA | $257.7 | 39% below |
ALNY is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ALNY on trend strength, trading above more of its moving averages.
ALNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $117.5 | $137.6 | +17% |
| 2021 | $137.6 | $194.4 | +41% |
| 2022 | $194.4 | $237.9 | +22% |
| 2023 | $237.9 | $191.4 | -20% |
| 2024 | $191.4 | $238.0 | +24% |
| 2025 | $238.0 | $400.6 | +68% |
| 2026 YTD | $400.6 | $156.7 | -61% |
ALNY is down 61% so far in 2026, after finishing higher in five of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ALNY on returns for 2026, with the stronger performance.